Purpose: Vascular endothelial growth factor (VEGF) is one of the most important growth factors for metastatic tumors. To clarify the role of VEGF-A and C in patients with peptic ulcer disease (PUD) or gastric cancer (GC), we evaluated the expression levels of these two molecules. We also analyzed the effect of Helicobacter pylori infection on VEGF-A and C expression levels. Materials and Methods: Patients with dyspepsia who needed diagnostic endoscopy were selected and divided into three groups: nonulcer dyspepsia (NUD), PUD, and GC, according to their endoscopic and histopathological results. Fifty-two patients with NUD, 50 with PUD, and 38 with GC were enrolled in this study. H. pylori infection was diagnosed by the rapid urease test. After RNA extraction and synthesis of cDNA, the expression levels of VEGF-A and C were determined by quantitative reverse transcriptase polymerase chain reaction. Results: The VEGF-C expression level in the PUD and GC groups was significantly higher than that in the NUD group. Moreover, the VEGF-A expression level in the PUD and GC groups was higher than in the NUD group, although the differences were not statistically significant. Significant positive correlations were also observed between the expression levels of these two molecules in the PUD and GC groups. In addition, the expression levels of these two molecules were higher in H. pylori positive patients with PUD or GC than in H. pylori negative patients of the same groups; however, these differences did not reach statistical significance. Conclusions: Up-regulation of VEGF-C expression during gastric mucosal inflammation may play a role in the development of peptic ulcers or GC.
Introduction
Dyspeptic disorders such as gastroesophageal reflux, gastritis, peptic ulcer disease (PUD), and gastric cancer (GC) are major medical conditions. 1 PUD is usually associated with a reduced health-related quality of life, whereas GC is the fourth most common cancer and the second leading cause of cancer-related deaths worldwide. 2, 3 Host factors such as genetics and nutrition, and environmental factors such as Helicobacter pylori infection may be involved in the development of these conditions. 1, 4 H. pylori infection has been shown to be a major risk factor for the development of PUD and GC. 5, 6 However, despite several investigations, it is still not completely understood why the major-ity of infected people (80%~90%) carry and spread the bacterium while they are asymptomatic, or why only a small percentage of infected people develop peptic ulcers, whereas others develop GC. 6 Host immune responses against H. pylori can result in chronic inflammation in the gastric mucosa, which in turn leads to the development of pathological conditions including PUD and GC. 5, 6 Vascular endothelial growth factors (VEGFs) are glycoproteins secreted by tumor cells that are the most important factors in angiogenesis and tumor metastasis. 7 The VEGF family includes VEGF-A to F and placental growth factor. 7, 8 Studies have shown that VEGF-A and B play a key role in blood vessel growth, whereas VEGF-C and D are important for the growth of lymphatic vessels. 9, 10 The role of VEGFs, particularly VEGF-A, C, and D in promoting angiogenesis and metastasis of many cancers including GC, has been previously discussed. 11, 12 Moreover, inflammatory cytokines such as interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha (TNF-α) are generally responsible for the epigenetic alteration of gastric epithelial cells. 13 These cytokines induce the mediators of angiogenesis, including VEGF and IL-8, which promote angiogenesis in cancer. These mediators also promote angiogenesis during chronic inflammation such as cardiovascular disease, rheumatoid arthritis, diabetic retinopathy, delayed-type hypersensitivity, and asthma. 14 It has been shown that VEGF-A expression is up-regulated in response to H. pylori infection. 15 Indeed, H. pylori activates the c-Jun N-terminal Kinases (JNK) signaling pathway, which leads to transactivation of the VEGF-A promoter. VEGFs promote angiogenesis, which is a pathophysiological mechanism that can result in inflammatory and ulcerative epithelial lesions and malignant tumor growth and metastasis. 15 To understand the role of VEGFs in the pathogenesis of H.
pylori-related gastric abnormalities, the mRNA expression levels of VEGF-A and C were determined in patients with peptic ulcers or GC, and compared with those with non-ulcer dyspepsia (NUD).
Materials and Methods 
Patients and sampling

Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)
VEGF-A, VEGF-C and hypoxanthine-guanine phosphoribosyl transferase (HGPRT, for normalization), sequences were obtained from the GenBank (Table 1) . Primers for amplification of VEGF-A, VEGF-C, and HGPRT were designed using the Beacon designer 7 software and synthesized by TIBmol (Germany) ( Table 1) .
qRT-PCR was performed using 96 well plates (Bio-Rad Laboratories Inc., Hercules, CA, USA) in a volume of 20 μl containing 
Statistical analysis
Statistical analysis was performed using the SPSS Statistical 
Results
Fifty-two patients with NUD, 50 with PUD, and 38 with GC were enrolled in this study ( 
Relative expression of VEGF-C
Gene expression levels of VEGF-C were determined using qRT-PCR and normalized to the expression level of HGPRT for each individual sample. The results show that the relative expression levels of VEGF-C were higher in GC and PUD patients than in NUD patients (P＜0.000 and P＜0.000, respectively; Table 3 , Fig. 1 ). Values are presented as mean±standard deviation or number (%). NUD = non-ulcer dyspepsia; PUD = peptic ulcer disease; GC = gastric cancer; ND = not defined. Values are presented as mean±standard error. VEGF = vascular endothelial growth factor; PUD = peptic ulcer disease; GC = gastric cancer; NUD = non-ulcer dyspepsia. *Compared with NUD patients. P≤0.05 considered as significant.
Furthermore, the relative gene expression levels of VEGF-C between the H. pylori positive and negative patients were not significantly different among the NUD, PUD, and GC patient groups (P=0.088, P=0.061, and P=0.714, respectively; Table 4 , Fig. 2 ).
Relative expression of VEGF-A
Gene expression levels of VEGF-A were also measured using
qRT-PCR and normalized to the expression level of HGPRT for each individual sample. Patients with PUD or GC showed higher VEGF-A expression levels than patients with NUD, but the differences were not statistically significant (P=0.201 and P=0.217, respectively; Table 3 , Fig. 1 ). Moreover, VEGF-A was expressed at higher levels in H. pylori positive patients than in H. pylori negative patients in all three groups; however, these differences did not reach statistical significance (P=0.164, P=0.927, and P=1.000, respectively; Table 4 and Fig. 2 ).
Correlation between VEGF-A and VEGF-C expression
Positive correlation was found between VEGF-A and VEGF-C expression in patients with PUD (r=0.458, P＜0.000) or GC (r=0.38, P＜0.000), but not in patients with NUD (Table 5) .
Discussion
This study evaluated the expression levels of VEGF-A and C in patients with PUD or GC compared with NUD patients as a con- ) of VEGF-A and VEGF-C in patients with NUD, PUD, and GC. *Denotes significant differences between groups. VEGF = vascular endothelial growth factor; NUD = non-ulcer dyspepsia; PUD = peptic ulcer disease; GC = gastric cancer. 
16-18
Previous studies have shown the expression of VEGF-C in tissues such as the placenta, ovary, small intestine, skeletal muscle, colon, and spleen. 19, 20 Karpanen et al. 21 showed that due to its as- size and lymph node metastasis. 18 Furthermore, using inducible mouse tumor models, silencing of the VEGF-C gene resulted in a significant reduction of tumor size in the experimental mice compared to that in the control mice. 18 In addition, several studies have shown that VEGFs produced by the tumor cells can suppress the maturation of antigen-presenting cells, especially dendritic cells, which may lead to immune evasion and tumor progression. 27 In our study, similar to previous studies on GC, 12, 20 we found significantly higher VEGF-C expression levels in patients with GC than in those with NUD.
We also found a significant increase in the VEGF-C expres- Because of the increased expression of VEGF-C in both GC and PUD patients, we assumed that expression of this glycoprotein is increased not only during cancer metastasis but also during chronic inflammation. 29, 32 Thus, the factors that cause inflammation, including infectious agents and carcinogens, may also lead to chronic inflammation by stimulating the production of proinflammatory cytokines and inducing production of VEGF-C.
Therefore, the production of VEGF-C in peptic ulcers can lead to the progression of inflammation and development of cancer. Similar to our study, George et al. 33 showed that VEGF-A expression levels were increased in the sera from patients with colorectal cancer, suggesting that VEGF-A was involved in the progression of this malignancy. Another study also showed increased VEGF expression level in the advanced stages of GC compared to that in the earlier stages. 34 In our study, despite the increased expression of VEGF-A observed, the differences between GC patients and controls were not statistically significant. Our findings could be influenced by the fact that we enrolled patients who had recently been diagnosed with GC, most of whom had early-stage disease with typical lower VEGF-A expression levels.
VEGF-
In addition, our results showed that the expression levels of both VEGF-A and VEGF-C were higher in H. pylori positive patients with PUD or GC than in H. pylori negative patients of the same groups, although this increase was also not statistically significant. One study showed that H. pylori induced the expression of VEGF-A via the phosphorylation of MEK/ERK transactivators and the activation of the JNK cascade. 35 In that study, the binding of SP1 and SP3 proteins to the VEGF-A gene promoter stimulated VEGF-A expression. Furthermore, the same study showed that H. pylori strains with the cytotoxicity-associated gene (cag) pathogenicity island can activate the JNK cascade, while cag-negative strains cannot activate this pathway. Indeed, cag is a type IV secretion effector of H. pylori that is closely associated with the development of GC. 35 These findings suggest an important role for cag-positive H. pylori strains in the production of angiogenic factors that lead to cancer metastasis. 15 Although we did not examine the presence of cag in our samples, the prevalence of cag positive H. pylori strains is approximately 57% in patients infected with H.
pylori, based on a 2012 study by Ajami et al. 36 in the north of Iran.
In the present study, no significant increase in the VEGF-A and VEGF-C expression was found in the H. pylori positive patients compared with that in the H. pylori negative patients. This could be because our study did not differentiate between cag-positive and cag-negative strains of H. pylori. In addition, the unequal numbers of patients in the H. pylori positive and H. pylori negative groups might have biased the results.
The present study also determined the correlation between the expression levels of VEGF-A and VEGF-C by Pearson's correlation coefficient, which showed a significant positive correlation between the two variables. In agreement with our results, several studies have shown that VEGF-A and C have a synergistic effect, such that that production of one factor can stimulate the production of the other. 37 Moreover, a study performed on patients with colorectal cancer 33 showed a significant correlation between these two glycoproteins.
In summary, we report that inflammation of the gastric mucosa may result in the up-regulation of VEGF-C expression, which in turn, plays a role in the development of gastritis, peptic ulcers, premalignant changes, and ultimately, GC. The use of other techniques such as immunohistochemistry in addition to real-time PCR would provide a more accurate assessment of VEGF-A and VEGF-C protein levels, and likely demonstrate the increased expression of these glycoproteins. There were no follow-up studies on these patients, and thus we did not assess the expression of these glycoproteins during the various disease stages.
